Insulet Corporation (PODD) Stock Price, Fundamentals & Analysis

What PODD does

Insulet Corporation (PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. Its main products are the Omnipod platform, including the Omnipod 5 automated insulin delivery system, the Omnipod DASH insulin management system, and the Omnipod Insulin Management System. The company also supplies pods for Amgen’s Neulasta Onpro kit. Insulet sells its products through the pharmacy channel and independent distributors.

Key numbers explained

• 136,49 USD is the latest trading price for PODD.
• The trailing P/E ratio (25,6) divides the current share price by the last 12 months of earnings per share (5,33 USD), showing how much investors pay for each dollar of recent earnings.
• The forward P/E ratio (17,7) uses expected future earnings, which can be lower if the market anticipates growth.
• 0% dividend yield and 0% of earnings paid out as dividends mean the company does not currently distribute cash to shareholders.
• 1,08 beta indicates the stock’s price tends to move slightly more than the overall market.
• 9,47 mld. USD market cap reflects the total value of all outstanding shares.
• 23,5% revenue growth year over year shows how quickly the company’s top line has expanded on a trailing 12-month basis.
• 12,3% profit margin and 16,2% operating margin measure how much of each revenue dollar remains as profit after costs and operating expenses.
• 26% return on equity indicates the company generates a 26-cent profit for every dollar of shareholder equity.

Recent news

• Insulet is set to participate in the Bernstein Insights: Healthcare Leaders and Disruptors forum.
• BCSM exited Insulet Corporation (PODD) but maintained a watchlist status.
• The stock appears in a list of two S&P 500 stocks with impressive fundamentals and one the author turns down.
• A comparison piece asks why one might pay more for Stryker when BSX stock is on sale.
• Beta Bionics’ insulin patch pump received FDA nod.
• A piece questions whether it is prudent to retain Insulet stock in a portfolio for now.

What to watch

Investors often track how PODD competes with peers such as Dexcom (DXCM) and how broader sector trends in the S&P 500 affect medical device stocks. Regulatory decisions, product adoption rates, and reimbursement policies can influence demand for insulin delivery systems. Earnings reports, such as the upcoming report on 5 nov. 2026, often drive short-term price movements.